The Nigerian pharmaceutical landscape is undergoing a significant structural transformation, marked by a sharp decline in reliance on imported finished products and a concerted push toward international manufacturing standards. The National Agency for Food and Drug Administration and Control (NAFDAC) has officially projected that approximately 60 percent of the nation’s pharmaceutical manufacturing facilities will be fully compliant with global Good Manufacturing Practice (GMP) standards by this time next year. This ambitious target represents a watershed moment for a sector that, until recently, struggled with high rates of high-risk classifications and systemic quality control deficiencies.

The announcement was made by the NAFDAC Director-General, Prof. Mojisola Adeyeye, during the 2026 week of the Association of Industrial Pharmacists of Nigeria (NAIP), Ogun State Zone, hosted in Ijoko. Represented by Pharmacist Samson Fatoki, the agency’s Chief Regulatory Officer and Lead GMP Inspector, the NAFDAC leadership underscored that this upward trajectory in quality compliance is the direct result of aggressive regulatory reforms initiated to bolster domestic production capacity and ensure the safety of the Nigerian drug supply chain.

A Decade of Regulatory Transformation: From Crisis to Compliance

The current progress in the pharmaceutical sector is best understood when viewed against the backdrop of the comprehensive GMP roadmap implemented between 2017 and 2019. During that period, an audit conducted with the support of the United Nations Industrial Development Organization (UNIDO) and international partners revealed a sobering reality: over 85 percent of Nigerian pharmaceutical manufacturers were categorized as high-risk, with less than five percent meeting the stringent international standards required to guarantee drug efficacy and safety.

To reverse this trend, NAFDAC introduced a series of rigorous, risk-based regulatory interventions. These included mandatory, extensive layout reviews for all manufacturing facilities, the centralization of GMP inspection processes, and a proactive, collaborative engagement strategy with stakeholders to guide them through the transition. Since 2021 alone, the agency has evaluated over 200 pharmaceutical plant layout applications, encompassing both new greenfield projects and the extensive retrofitting of legacy facilities.

The chronological growth of the sector highlights the effectiveness of these measures. In 2019, there were 165 manufacturing sites in Nigeria. By September 2026, that figure had expanded to 184. More importantly, the percentage of these firms meeting GMP standards has seen a parabolic rise, climbing from a meager five percent in 2019 to approximately 32 percent by March 2026, with current inspections indicating that the industry is steadily tracking toward the 40 percent mark and eventually the 60 percent threshold projected for late 2027.

The Macroeconomic Shift: Reducing Import Dependence

One of the most profound impacts of these regulatory reforms is the drastic reduction in the volume of imported pharmaceuticals. NAFDAC data indicates that in 2021, Nigeria imported over 450 billion metric tonnes of drugs. As of late 2026, that figure has plummeted to approximately 100 billion metric tonnes—a reduction exceeding 70 percent.

This pivot is largely attributed to the "5+5" regulatory policy, a strategic framework designed to incentivize the migration of pharmaceutical production from overseas to domestic facilities. Under this policy, importers are granted an initial five-year window, followed by a second five-year period, during which they are expected to establish local manufacturing capabilities for the medicines they import. This mechanism has effectively forced a shift in business models, with numerous companies transitioning from simple trading to value-added local manufacturing.

Furthermore, NAFDAC has strategically expanded its "Ceiling List"—a register of medicines that can be produced locally—from nine to 36 product categories. By barring the importation of these products, the agency has created a protected market environment that encourages domestic investment. By March 2026, at least 78 distinct product lines had been identified for migration to local production, a trend that is expected to continue as regulatory barriers to entry for importers remain high while support for local manufacturers increases.

Strategic Imperatives: Innovation and Global Integration

While the increase in manufacturing volume is a positive development, industry experts are stressing that quantity must not come at the expense of quality or technological relevance. During the NAIP Ogun State event, Chief Varkey Verghese, Managing Director of Jawa International and the event’s "Father of the Day," emphasized that the future of the Nigerian pharmaceutical sector hinges on "continuous innovation."

Verghese argued that global advancements in biotechnology, personalized medicine, and AI-driven production are rapidly outpacing traditional manufacturing models. He urged Nigerian pharmacists and plant owners to look beyond basic compliance and focus on optimizing product formulations, packaging, and supply chain integrity. According to Verghese, compliance with GMP is not merely a legal hurdle to be cleared for NAFDAC certification, but an ethical obligation to the Nigerian populace.

Prof. Adeyeye echoed this sentiment, warning that the global pharmaceutical environment is evolving too rapidly for the local industry to remain static. "Developments in artificial intelligence, biotechnology, and advanced therapy medicinal products are reshaping global healthcare," she noted. "Nigerian manufacturers must position themselves to adopt these emerging technologies to compete on the international stage."

Strengthening the Supply Chain: Technology as a Safeguard

Beyond the factory walls, NAFDAC is leveraging digital transformation to secure the pharmaceutical supply chain. To combat the scourge of substandard and falsified medicines, the agency has rolled out several high-tech initiatives, including:

• The Scan to Verify App: Enabling consumers to authenticate drugs in real-time.
• The NAFDAC Green Book: A digital repository of registered medicines to increase transparency.
• The MedSafety Application: A tool for reporting adverse drug reactions to facilitate pharmacovigilance.
• Mobile Authentication Service (MAS): Utilizing SMS-based verification to ensure that products reaching the end-user are genuine.

These tools are part of a broader strategy aimed at achieving WHO Maturity Level Four—a designation that would place NAFDAC among the most advanced regulatory bodies globally. Attaining this level would not only enhance public trust in domestically produced medicines but would also pave the way for Nigerian manufacturers to participate in the Pharmaceutical Inspection Co-operation Scheme (PIC/S), effectively opening up export markets for "Made in Nigeria" pharmaceuticals.

Collaborative Leadership and Future Prospects

The NAIP Ogun State Week served as a critical platform for this discourse, with leadership from the national and state chapters reiterating the need for sector-wide unity. Pharm. (Sir) Bankole Ezebuilo, the National Chairman of NAIP, represented by Pharmacist Emeka Ndineche, lauded the Ogun State zone for its role in fostering professional development and industry growth.

The event featured intensive plenary sessions focused on "Safeguarding Medicines: Advancing Innovation, Compliance and Patient Trust" and "Ensuring Drug Product Safety: Control Strategies from Development to Distribution." These discussions, moderated by senior industry professionals like Pharm. Ariike Mbaneme of May & Baker Plc and Pharm. Emmanuel Ogana of Ranbaxy-Sun Pharma Nigeria Limited, highlighted a recurring theme: the necessity of a tripartite approach involving regulators, manufacturers, and health professionals to ensure that the progress made in the last five years is sustained.

As the industry looks toward 2027, the implications of these developments are clear. The combination of restrictive import policies, rigorous facility upgrades, and technological adoption is creating a more resilient and self-sufficient pharmaceutical sector. If the 60 percent GMP compliance target is met, it will signal that Nigeria is no longer merely a destination for foreign drug dumping, but an emerging hub for pharmaceutical excellence within the African continent. The challenges remain substantial—ranging from infrastructure deficits to the high cost of raw material importation—but the momentum established by NAFDAC and the industrial pharmacy community suggests a sector that is increasingly confident in its ability to meet the health security needs of a growing nation.